Key result
Myocardial RNA-splice signature shows modest discrimination for persistent hypertrophy with an AUC of ~0.65.
Why the study?
Left ventricular hypertrophy does not regress equally in all patients after aortic valve replacement. This study examined whether myocardial splice differences associated with remodelling labels persist under leave-one-out exclusion and how they affect reference transcripts and proteins.
Observational (n=41)
Although 22 myocardial alternative splicing events (including a known 5-amino-acid DGLUCY variant) were stably associated with post-AVR ventricular remodelling labels across leave-one-out analyses, they provided only modest individual-level discrimination (AUC 0.648) and require independent validation.
Answers are grounded in this paper and cite their sources.
Stable splice events showed only modest discrimination of persistent hypertrophy; hypothesis-generating for transcriptomic biomarkers post-AVR and leaves open independent validation.
Background Left ventricular hypertrophy does not regress equally in all patients after aortic valve replacement. We examined whether myocardial splice differences associated with remodelling labels persisted after individual samples were excluded, and what these differences could change in reference transcripts and proteins. Results We reanalysed 41 public myocardial RNA-sequencing samples labelled as persistent hypertrophy (HYP, n = 21) or reverse remodelling (REV, n = 20). Of 156,111 candidate splice events, 70 met the full-cohort selection criteria. Twenty-two events in 19 genes were selected with unchanged direction in all 41 leave-one-out analyses. Both local splice alternatives matched reference transcripts for 16 events. A score derived separately within each training set could be calculated for every excluded sample. Its area under the receiver operating characteristic curve was 0.648, compared with 0.998 when selection and assessment used the full cohort. DGLUCY long-site inclusion averaged 0.766 in HYP and 0.605 in REV; the difference remained positive after each sample was removed. Complete reference sequence comparisons linked the 15-base splice-site difference to the five-amino-acid segment AGAYK. This sequence alternative is already recorded in UniProt. Conclusions The analysis identified internally stable myocardial splice associations and mapped selected events to reference sequences. The modest leave-one-out discrimination and unresolved correspondence between the 41 public samples and the original 40-person clinical cohort preclude a validated prognostic interpretation. Independent outcome-linked data are needed to test these associations.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted an observational in Severe aortic stenosis undergoing surgical aortic valve replacement (n=41). Myocardial alternative splicing score (persistent hypertrophy label, HYP) vs. Reverse remodelling label (REV) was evaluated on Discrimination between persistent hypertrophy (HYP) and reverse remodelling (REV) labels using leave-one-out cross-validated myocardial splice score (MD 0.164 (Leave-one-out AUC 0.648)). Myocardial RNA-sequencing splice analysis identified 22 stable splice events across leave-one-out exclusions, yielding a modest leave-one-out AUC of 0.648 for discriminating persistent hypertrophy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: